Clinical Research Directory
Browse clinical research sites, groups, and studies.
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells（QT-019C） in With Relapse/Refractory Autoimmune Diseases.
Official title: A Clinical Study Evaluating the Safety and Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2026-03
Completion Date
2028-09
Last Updated
2026-02-13
Healthy Volunteers
No
Interventions
UCAR-T cells
QT-019C will be administered intravenously as per the schedule specified in the protocol.
Locations (1)
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China